Figure 4.

CF₃-Enigmol and CF₂-Enigmol in mouse xenograft models of prostate cancer. Nude mice (n = 10–11 per group) with palpable tumors derived from PC-3 human prostate cancer cells were treated once daily via oral gavage with either vehicle (95:5 olive oil/EtOH), Enigmol (3 or 10 mg/kg), or CF₃-Enigmol (3 or 10 mg/kg) in the first study (a–c), or with either vehicle (95:5 PEG400/Tween80), Enigmol (10 mg/kg), or CF₂-Enigmol (10 or 30 mg/kg) in the second study (d–f). Tumor volume and change in body weight were measured periodically. At the end of each study, tumors were harvested, and accumulation was measured using LC-MS/MS. Data represent the mean ± SEM. Statistical significance (*p < 0.05, **p < 0.01, or ***p < 0.001) of tumor growth inhibition was assessed via a linear mixed model for repeated measurement with the autoregressive covariance structure using Statistical Analysis System (SAS) software. Significance of change in body mass was determined using One-Way ANOVA followed by Sidak’s multiple comparison test.